Abivax SA
PAR:ABVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Abivax SA
Net Issuance of Common Stock
Abivax SA
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abivax SA
PAR:ABVX
|
Net Issuance of Common Stock
€353.4m
|
CAGR 3-Years
97%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Net Issuance of Common Stock
€30m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
153%
|
CAGR 10-Years
-3%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Net Issuance of Common Stock
€51k
|
CAGR 3-Years
117%
|
CAGR 5-Years
49%
|
CAGR 10-Years
-15%
|
|
|
Inventiva SA
PAR:IVA
|
Net Issuance of Common Stock
€206.4m
|
CAGR 3-Years
186%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
Net Issuance of Common Stock
$44k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-66%
|
CAGR 10-Years
-57%
|
|
|
DBV Technologies SA
PAR:DBV
|
Net Issuance of Common Stock
$276.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
1%
|
|
Abivax SA
Glance View
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
See Also
What is Abivax SA's Net Issuance of Common Stock?
Net Issuance of Common Stock
353.4m
EUR
Based on the financial report for Dec 31, 2025, Abivax SA's Net Issuance of Common Stock amounts to 353.4m EUR.
What is Abivax SA's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
68%
Over the last year, the Net Issuance of Common Stock growth was 81 326%. The average annual Net Issuance of Common Stock growth rates for Abivax SA have been 97% over the past three years , 68% over the past five years .
